Описание
Pantoprazole has minimal CYP2C19 inhibitory activity compared with omeprazole, making it the preferred PPI choice in patients on clopidogrel.
Механизм
Pantoprazole does not significantly inhibit CYP2C19, so clopidogrel bioactivation is largely preserved compared with omeprazole or esomeprazole.
Клиническое значение
Observational data suggest no significant increase in cardiovascular events with pantoprazole + clopidogrel; this interaction is less clinically significant than the omeprazole-clopidogrel combination.
Тактика ведения
Pantoprazole is the preferred PPI for gastroprotection in patients on clopidogrel; routine monitoring is not required beyond standard care.
Медицинский отказ от ответственности
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.